论文部分内容阅读
目的:探讨E-选择素(E-selectin)表达对上皮性卵巢癌的诊断价值。方法:采用酶联免疫吸附试验(ELISA)检测62例卵巢癌患者(恶性组)、30例卵巢囊肿患者(良性组)和30例健康志愿者(对照组)血清E-选择素含量的变化。结果:ELISA结果显示:卵巢癌组治疗前血清sE-selectin明显增高,与对照组及卵巢囊肿组的差异有统计学意义(P<0.05);且与淋巴结转移、肿瘤分化程度和临床TNM分期明显相关。行根治性手术组术后血清sE-selectin降低,与对照组和卵巢囊肿组的差异有统计学意义(P<0.05),姑息性手术组血清sE-selectin则无显著变化(P>0.05)。结论:利用酶联免疫吸附试验检测E-选择素的表达有助于综合判断卵巢癌的恶性程度和转移潜能,可能成为辅助诊断和判断预后有价值的新指标。
Objective: To investigate the diagnostic value of E-selectin expression in epithelial ovarian cancer. Methods: The changes of serum E-selectin levels in 62 patients with ovarian cancer (malignant group), 30 patients with ovarian cyst (benign group) and 30 healthy volunteers (control group) were detected by enzyme linked immunosorbent assay (ELISA) Results: The results of ELISA showed that the serum level of sE-selectin in ovarian cancer group was significantly higher than that in control group and ovarian cyst group before treatment (P <0.05), and was significantly correlated with lymph node metastasis, tumor differentiation and TNM stage Related. The level of sE-selectin in the radical surgery group was significantly lower than that in the control group and the ovarian cyst group (P <0.05), while there was no significant change in the sE-selectin level in the palliative surgery group (P> 0.05). Conclusion: The use of enzyme-linked immunosorbent assay to detect the expression of E-selectin contributes to the comprehensive evaluation of malignancy and metastatic potential of ovarian cancer, and may be a new index to assist diagnosis and prognosis.